STING1 and neoplasm: As some intriguing clinical trials have shown, in the later stages of tumor development, agonists of the cGAS-STING pathway, acting as unbiased perturbations to the entire tumor, paradoxically have little effect on tumor progression.251,252 This is contrary to the significant anti-tumor tendency of the autonomous cGAS-STING pathway in immune cells.